Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.

26 Feb 2016

PharmaMar begins PM184 Phase II trial in advanced breast cancer patients

PharmaMar has announced the start of an open-label multi-centre two-stage Phase II trial with the anti-tumour drug PM184. The trial will be conducted in 10 European clinical centres and will include 106 patients. The trial will focus on patients with hormone-receptor positive, HER2-negative, locally advanced and/or metastatic breast cancer, who have experienced progression following earlier treatment with anthracyclines and taxanes.

26 Feb 2016

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

AbbVie, a global biopharmaceutical company, today announced the European Medicines Agency has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML).

26 Feb 2016

Nearly two-thirds of herbal medicines have potential health risks to cancer patients

Nearly two-thirds of the herbal medicines used by cancer patients in the Middle East have potential health risks, according to a new survey led by Assistant Professor Eran Ben-Arye, of the Technion-Israel Institute of Technology.

26 Feb 2016

Queen's University leads world's first trial of new combination treatment for advanced prostate cancer

Queen's University Belfast, in partnership with the Belfast Trust, is leading the world's first ever trial of a new combination of cancer therapies for patients with advanced prostate cancer, with the hope of prolonging their lives.

26 Feb 2016

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings.

26 Feb 2016

Rigel begins fostamatinib Phase 2 trial for treatment of patients with autoimmune hemolytic anemia

Rigel Pharmaceuticals Inc. today announced that it has initiated a Phase 2 clinical trial to evaluate fostamatinib, its oral SYK inhibitor, as a potential treatment for autoimmune hemolytic anemia (AIHA).

25 Feb 2016

Moffitt researchers develop novel therapeutic strategy to keep resistant cells in check

Despite numerous advances in oncology since the War on Cancer began, many patients develop resistance to standard therapies and eventually relapse. Moffitt Cancer Center researchers hope to improve treatment outcomes with development of a novel therapeutic strategy, called adaptive therapy, which is based on evolutionary principals and aims to keep resistant cells in check by maintaining a population of chemo-sensitive cells.

25 Feb 2016

New report reveals malignant brain tumors as most common cause of cancer-related deaths in young people

A new report published in the journal Neuro-Oncology and funded by the American Brain Tumor Association finds that malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young adults aged 15-39 and the most common cancer occurring among 15-19 year olds.

25 Feb 2016

Research: Impaired immune response significantly involved in rare autoimmune diseases

In the context of the multicentre EU project "INTRICATE" under the management of Renate Kain of the Clinical Institute for Pathology of MedUni Vienna, the effects of infections on the generation of rare autoimmune diseases such as granulomatous polyangiitis (GPA), a systemic disease of the vascular system, are examined.

25 Feb 2016

Gene expression analysis points metastatic CRC patient to successful irbesartan therapy

A patient with recurrent metastatic colorectal cancer has been successfully treated with the angiotensin receptor blocker irbesartan, researchers report.

24 Feb 2016

IMP's Johannes Zuber receives German Cancer Prize 2016

Johannes Zuber, group leader at the Research Institute of Molecular Pathology (IMP) in Vienna, receives the German Cancer Prize 2016 in the category of experimental cancer research.

24 Feb 2016

Investigating mechanism behind development of high-grade serous ovarian cancer

Rutgers Cancer Institute of New Jersey researcher Michael L. Gatza, PhD, has received a $747,000 Pathway to Independence Award (R00-CA166228) from the National Cancer Institute to explore the mechanism behind the development of a subtype of ovarian cancer known as high-grade serous ovarian cancer.

24 Feb 2016

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Cancer immunology is based upon boosting the body's own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells - one of the immune system's primary weapons - to treat three different types of blood cancer that often defy existing therapies.

24 Feb 2016

Gamma Knife and RapidArc equally effective at eradicating cancer in the brain

While two advanced radiosurgery approaches — Gamma Knife and RapidArc — offer different strengths, they are equally effective at eradicating cancer in the brain, say researchers at Sidney Kimmel Cancer Center.

24 Feb 2016

New clinical trial launched to test potential drug that could help immune system combat cancer

Cancer Research UK's Centre for Drug Development, in partnership with Amgen Inc., has launched a new clinical trial to test a drug that could stop a patient's immune system from protecting tumours.

24 Feb 2016

New definitions and clinical criteria for sepsis, septic shock

Clifford S. Deutschman, MS, MD, vice chair of research in the Department of Pediatrics at Cohen Children's Medical Center and an investigator at The Feinstein Institute for Medical Research , presented new definitions and clinical criteria for sepsis and septic shock at the Society of Critical Care Medicine's 45th Critical Care Congress in Orlando, FL.

24 Feb 2016

UMMC surgeons develop a program to direct critically ill patients to appropriate treatment location

A team of surgeons at the University of Maryland Medical Center has developed a program that utilizes its Shock Trauma Center (STC) model to direct critically ill non-trauma patients to the appropriate treatment location and get them into an operating room and hospital intensive care unit (ICU) bed as quickly as possible.

24 Feb 2016

Maryland Proton Treatment Center completes first patient treatment with Varian ProBeam system

Varian Medical Systems, today announced the Maryland Proton Treatment Center successfully completed its first patient treatment with the Varian ProBeam system. The MPTC at the University of Maryland BioPark in West Baltimore houses five treatment rooms and is the first in the Eastern US to offer image-guided intensity-modulated proton therapy (IMPT) with a ProBeam system.

24 Feb 2016

Researchers devise new approach to improve current T-cell therapy methods

T-cell therapy, a form of immunotherapy that uses a patient's own immune cells to attack their cancer, has been making waves recently. The "living" therapy involves engineering the patient's T cells in the laboratory to carry new proteins that guide the immune cells directly to tumor cells, allowing the engineered T cells to attack and kill the cancer.

23 Feb 2016

Oncology News and Research

Further Reading

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

PharmaMar begins PM184 Phase II trial in advanced breast cancer patients

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

Nearly two-thirds of herbal medicines have potential health risks to cancer patients

Queen's University leads world's first trial of new combination treatment for advanced prostate cancer

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Rigel begins fostamatinib Phase 2 trial for treatment of patients with autoimmune hemolytic anemia

Moffitt researchers develop novel therapeutic strategy to keep resistant cells in check

New report reveals malignant brain tumors as most common cause of cancer-related deaths in young people

Research: Impaired immune response significantly involved in rare autoimmune diseases

Gene expression analysis points metastatic CRC patient to successful irbesartan therapy

IMP's Johannes Zuber receives German Cancer Prize 2016

Investigating mechanism behind development of high-grade serous ovarian cancer

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Gamma Knife and RapidArc equally effective at eradicating cancer in the brain

New clinical trial launched to test potential drug that could help immune system combat cancer

New definitions and clinical criteria for sepsis, septic shock

UMMC surgeons develop a program to direct critically ill patients to appropriate treatment location

Maryland Proton Treatment Center completes first patient treatment with Varian ProBeam system

Researchers devise new approach to improve current T-cell therapy methods

Event guide: The 9th DDR Inhibitors Summit 2026 eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News